Delayed graft function is an important determinant of patient and graft survival. A complex of pathologic mechanisms intervenes in the pathophysiology of this outcome. This paper reviews the main processes involved in delayed graft function as they relate to five chronologically related stages: donor tissue quality, brain death and related stress, preservation variables, immune factors, and recipient variables.
Introduction
The term "delayed graft function" (DGF) describes acute transplant kidney dysfunction in the immediate postoperative phase after the transplant procedure. The most frequently used definition of DGF is the requirement for dialysis in the first week after kidney transplantation [1] . Other definitions have been used in the literature ( Table 1 ). The spectrum of immediate graft failure extends from mild prerenal azotemia to severe renal failure with biopsy-proven acute tubular necrosis. The term "slow graft function" (SGF) is sometimes used to describe milder forms of graft failure that fail to meet the DGF criteria; it involves a delayed fall in serum creatinine after the transplantation procedure. It is probable that many of these kidneys suffer from the same adverse effects as organs with frank DGF. Acute tubular necrosis of the transplanted kidney is, however, not synonymous with DGF, because other pathologic conditions can induce DGF. A list of different causes of DGF (or SGF) is included in Table 2 . The usual procedure for differentiating the pathologic entities of DGF is shown in Figure 1 .
The usual rate of DGF is 15 to 25% after kidney transplantation but depends on many variables. There will, of course, be an important difference between a center performing only living-related donation and a center with a policy of a high acceptance rate of marginal donors or of grafts with long cold ischemia times.
A possible important early consequence of DGF is an increased frequency of acute rejection, probably by exposure of hidden foreign antigens to the immune system of the recipient. This noxious combination of acute rejection and DGF is difficult to diagnose, and a high level of suspicion should be maintained. The frequency of the combination of acute rejection and DGF then shifts from the regular 25% to 40%, and many centers perform weekly surveillance kidney biopsies to rule out concomitant acute rejection. In the long run, DGF causes worse kidney function, indicating reduced nephron mass after recovery of the event; it is one of the most important independent variables of chronic allograft failure; and it impairs graft and patient survival ( Table 3) .
As with many definitions, the definition of DGF is subject to controversy. Alternative valid definitions of DGF have been proposed [2••]. The classic definition of DGF is the need for dialysis in the first week of transplanta-tion, but it is subject to the readiness of the transplant physician and the consulting nephrologist to perform dialysis on the allograft recipient. Frequently, only one dialysis is necessary for immediate postoperative hyperkalemia or volume overload after initial volume resuscitation. Rodrigo et al. [2••] proposed an earlier parameter of renal allograft function: the creatinine reduction ratio at day 2 (CCR2). The patients with immediate graft function had a better graft outcome at 1 year. CCR2 did correlate with kidney graft function during the first year. Interestingly, the patients with DGF as defined by the CCR2 had a worse outcome, whether or not they were dialyzed. Non-dialyzed DGF recipients performed as badly as their dialyzed counterparts. This means that there is a continuum of immediate graft dysfunction, important for the future of the graft, which is not captured by the actually accepted definition of DGF. Another paper also challenged the classic definition of DGF. The concept of SGF was introduced as a serum creatinine higher than 3 mg/dL on the fifth postoperative day, but without the need for dialysis. Significant risk factors for SGF were donor age older than 50 years and cold ischemia times longer than 24 hours. The risk factors for classic DGF are similar to those for SGF, although high panel-reactive antibodies (PRA) and donor creatinine levels above 1.7 mg/dL are additional risk factors for DGF [3] . Initial function of the graft significantly influenced the risk of acute rejection in the first year, with an incidence of rejection of 28% for immediate graft function, 38% for SGF and 44% for dialyzed DGF. The 5-year graft survival rate was significantly different: 89% for recipients with immediate graft function, compared with 72% for SGF and 67% for dialyzed DGF. The conclusion is that even moderate graft dysfunction may have a negative impact on long-term graft survival [3] .
Artificial neural network analysis and a nomogram were designed for prediction of DGF. The neural network was 63% sensitive and 65% specific; it provided superior prediction of the presence of DGF. Logistic regression techniques provided superior prediction of the absence of DGF [4] . Known risk factors for DGF include recipient pretransplant mean arterial pressure below 100 mm Hg, female donor to male recipient, cold ischemia time longer than 28 hours, peak PRA greater than 50%, and donor age older than 50 Numerous risk factors for DGF are known and can be categorized into five categories: donor tissue quality, brain death and related stress, preservation variables, immune factors, and recipient variables (Table 4 ). New and important processes in each of these categories will be reviewed.
Donor tissue quality
The United Network for Organ Sharing has defined expanded-criteria donors (ECD) as donors of 60 years or older or donors between 50 and 59 years with two of the following characteristics: donor history of cerebrovascular accident, donor history of arterial hypertension, and elevated serum creatinine (> 1.5 mg/dL). These ECD have been used more frequently in recent years to augment the donor pool. However, nonfunction of these grafts is more frequently encountered. In the study by Johnston et al.
[7] more than 8000 non-ECD were compared with 1312 ECD. ECD kidneys had a significantly increased incidence of cold ischemia time-dependent DGF. This result suggests that shorter cold ischemia times could be beneficial in more frail donors. Cecka [8] reevaluated the United Network for Organ Sharing da- 
DGF
Need for dialysis within the first week (sometimes excluding a single dialysis for hyperkalemia or volume overload) DGF-SGF Urine output < 1000 mL first 24 h < 10-30% decrease in serum creatinine in the first 24-72 h Serum creatinine > 3 mg/dL on day 5 Time needed to reach a glomerular filtration rate of > 10 mL/min Creatinine reduction ratio on day 2 (CCR2) Absence of spontaneous reduction of serum creatinine at day 1 tabase in 2002; more than 1200 ECD kidneys are transplanted each year in the United States. The 3-year graft survival is 68% but is worse than the survival of donor kidneys aged more than 5 years, showing a 81% graft survival.
Dopamine has already been tested many times in acute renal failure, without much evident success. In the setting of donor management, the effect of dopamine on immediate graft function was evaluated in a retrospective nonrandomized manner. Less DGF occurred in dopamine-treated recipients than in untreated recipients, and treatment was associated with an improvement in graft function at day 1. More patients reached a creatinine level above 2 mg/dL after 1 month: 82% versus 66% [9]. It is evident that this study needs to be reproduced in a blinded prospective randomized manner before de-finitive conclusions on the use of dopamine in the donor management setting can be drawn.
Living-related kidney donation is associated with an excellent long-term graft function and survival, better than with cadaveric donors. The literature on laparoscopic live-donor nephrectomy was recently reviewed [10•]. The procedure produced longer warm ischemia times but did not evoke an increase in DGF. The long-term effects were not studied, but graft function and survival at 1 year were identical to those of open live donor nephrectomy [11] . Early graft dysfunction was studied in 469 living donation kidney transplantations. The incidence of DGF and SGF was 4.7% and 11%, respectively, and strongly predisposed to acute rejection, which in turn compromised function and graft survival. Diabetes status in the recipient and prolonged warm ischemia time did correlate with both DGF and SGF [12] .
Because of the shortage of organs, many transplant centers are compelled to use donors they would not have used a few years ago. Also, elderly persons have been more frequently used as potential donors in the past decade. But donor age certainly has a impact on graft sur- vival and graft function; for example, the incidence of DGF was higher in donors older than 60 years (39% vs 29%). Older donor age seems also to affect recipient survival through increased cardiovascular mortality [13] . The Eurotransplant Senior program has been initiated as an "old for old" allocation program for local older donors to be used in local older recipients. DGF was as low as 12%, and patient and graft survival were favorable [14] . Interestingly, the preliminary result indicates a positive effect of shorter cold ischemia times on immediate graft function for the first recipient of the donor kidney pair [15] .
Using NHBD is another possibility of expanding the donor pool. In the past few years, some centers have become very specialized and have begun to share their experience [16] [17] [18] [19] [20] [21] . Although initial graft function is threatened in as many as 27.5 to 93% of recipients experiencing DGF, long-term patient and kidney survival at 5 years and graft function are similar to that in organs obtained from brain-death donors. An excellent review on this subject has recently been published [22••] . Centers that perform NHBD have an increase of 16 to 40% in available organs, with comparable costs. A United Network for Organ Sharing 2002 database analysis confirms the equal survival of kidneys from NHBD and brain-dead donors [8] .
Double kidney transplants from marginal adult donors were assessed in two databases [23, 24] . Double kidneys are used to circumvent the reduction in nephron mass that is expected in some circumstances, whereas otherwise these organs would have been discarded. Outcomes were studies in the United Network for Organ Sharing with 403 recipients and the Dual Kidney Registry with 287 recipients. The incidence of DGF was 27%, which was associated with prolonged cold ischemia times. Graft survival for DGF kidneys was worse than for kidneys with immediate graft function. Compared with singlekidney organ transplants from donors older than 55 years of age, graft survival was identical.
Diffuse intravascular coagulation is a frequent complication in dying patients and in brain-dead persons, and residual evidence of disseminated intravascular coagulation of donor origin in the transplanted kidneys is frequently seen. McCall et al. [25] found 8 positive cases in 230 biopsies, and this was more frequently associated with DGF. In comparison with control patients, graft function and survival were similar.
Brain death and related stress
A particularly bad prognosis is seen when the donor is an elderly person who died of acute intracerebral hemorrhage or thrombotic stroke. Compared with living donation, multivariate analysis showed that even after correction for cold ischemia time, donor brain death remained an independent factor for graft failure [26] . Grafts from brain-dead donors also show more acute rejection episodes [27•].
One study by Sanchez-Fructuoso et al.
[28] evidenced that brain death and DGF were among the strongest predictors for acute vascular rejection, together with previous transplantation, female gender, recipient age under 60 years, cerebrovascular disease as cause of donor death, and triple immunosuppressive therapy.
Free radical formation occurs during injury to donor tissues. Malondialdehyde levels in brain-death donor sera and preservation fluid were tested, and these levels were elevated twofold in DGF kidneys. Malondialdehyde levels correlated significantly with graft function at 1 and 4 years [29]. Anti-HLA Anti-ABO in ABO-incompatible living related donor Heart failure with reduced cardiac output Impaired effective circulating volume A combination of the above Two reviews of brain death and donor organ viability were recently published [30••,31••]. At the onset of brain death, kidney perfusion can be compromised. First, during agony of the donor, increases in intracranial pressure lead to excessive parasympathetic activity, which is counteracted by severe vasoconstriction caused by catecholamine release. This vasoconstriction causes relative organ hypoperfusion. Paralysis of spinal pathways ensues and causes sympathetic deactivation and decrease of vascular resistance. The donor becomes hemodynamically unstable and hypotensive, further threatening organ perfusion. Good clinical management of brain-dead donors must maintain perfusion pressure and vascular resistance in this phase to avoid peripheral organ ischemic damage. The ischemia/reperfusion injury already starts at the moment of brain death and affects early graft function. An inflammatory response with activation and infiltration of leukocyte populations and especially CD4 cells occurs, in addition to the release of cytokines like tumor necrosis factor-␣, interleukins (IL), and interferon; upregulation of intracellular adhesion molecules and vascular cell adhesion molecules; and expression of major histocompatibility complex class I and class II antigens [26,31••] .
Preservation variables
Varying episodes of cold and warm ischemia cause further ischemia/reperfusion injury. The accumulation of infiltrating T cells and the elevation of several cytokines and chemokines continue during this episode. T cell activation causes the generation of oxygen free radicals, and ischemia/reperfusion injury can unveil neoantigens that activate T cells. Murine models of ischemia/ reperfusion injury with CD4/CD8 knockout mice and T lymphocyte-deficient mice were protected from injury. Signal transducers and activator of transcription STAT 6 and IL-4-deficient mice showed more functional damage after ischemia/reperfusion injury [32] . Heat shock proteins-70 and heme oxygenase-1 (HO-1) are involved in cell survival pathways and are up-regulated during ischemia/reperfusion injury. Heat shock proteins reduced the nuclear binding of pro-inflammatory transcription factors and increased protective antioxidant capacity of cells. Heme oxygenase converts heme in carbon monoxide, biliverdin, and free iron, all of which have anti- of the presence of prostaglandin E1, nitroglycerin, and polyethylene glycol-superoxide dismutase. Machine perfusion of 82 renal grafts with Vasosol versus 80 grafts with Belzer revealed significantly less DGF with Vasosol than with Belzer perfusion (12.2% vs 21.2%) [35] . Carolina rinse solution, administered immediately before reperfusion, significantly ameliorated the detrimental effect of reperfusion in a porcine autotransplantation model, compared with kidneys reperfused at a lower pressure than blood pressure; urinary output and creatinine clearances were better with Carolina rinse solution [36] . The high Na + -low K + Belzer solution was compared with the low Na + -high K + University of Wisconsin formulation in pigs. Cold storage in Belzer resulted in reduction of delayed graft function and renal interstitial inflammation and fibrosis [37] . Oxidative damage during reperfusion injury was attenuated by the reactive oxygen species scavenger, ascorbic acid, added to Eurocollins. However, delayed graft function in the control group did not differ significantly from that in the treated group (29 vs 32%), although the treated group showed a trend toward shorter duration of DGF [38] . Other experimental trials with lidocaine-containing Eurocollins and pancaspase inhibition in a University of Wisconsin solution were published. Urinary lactic dehydrogenase, a tubular injury marker, was significantly lowered with the addition of lidocaine, and lipid peroxidation during reperfusion, measured with tissue malondialdehyde levels, was reduced [39] . The caspase-3 mediator of apoptosis was abrogated with University of Wisconsin solution plus a pancaspase inhibitor in mice. Caspase-3 activity was 100fold increased in cold ischemic kidneys compared with control mice. The pancaspase inhibitor prevented the formation of caspase-3 and the increase in caspase activity, and it further reduced renal tubular cell apoptosis and brush-border injury, suggesting a potential benefit in human cold ischemia-associated DGF [40] .
A meta-analysis of the effectiveness of pulsatile machine perfusion versus cold storage of kidneys in reducing DGF demonstrated that pulsatile machine perfusion led to a relative risk of DGF of approximately 80% compared with cold storage. This evidence is, however, based on smaller studies. Graft survival at 1 year demonstrated no statistically significant difference between machine perfusion and cold storage, but predictions at 10 years suggest potential improvements in DGF and graft survival of approximately 0 to 6% [41] .
Immune factors
Sensitized patients with a higher PRA are known to have a higher incidence of DGF. A potential mechanism could be that preformed antibodies go undetected in the crossmatch but reappear after transplantation and cause antibody-mediated rejection that is manifested as DGF. Increased HLA mismatching between donor and recipi-ent seems to be associated with DGF in multivariate analysis (PRA > 50%, RR 1.21) [1]. In a cohort of 1325 cadaver kidney transplant recipients, it was shown that presensitization increased the risk of DGF and that in turn DGF increased the risk of acute rejection. Among the patients who experienced DGF, 47% had acute rejection compared with an incidence of 30% among patients without DGF. The patients with greater than 50% PRA (either current or maximum) showed a significantly worse graft survival than did patients with less than 50% PRA. DGF significantly reduced graft survival in the early phase after transplantation [42] . In a retrospective study, previous sensitization of the recipient was associated with duration of DGF [43] . Noreen et al. [44] demonstrated that recipients with a positive crossmatch with historical sera demonstrated a higher incidence of DGF, acute rejection, and graft loss in the first year after transplantation compared with sensitized recipients with a negative historical crossmatch or unsensitized recipients. In multivariate analysis, only recipients with both a positive crossmatch and DGF were at significantly higher risk for graft loss [44] . Sijpkens et al. [45] demonstrated an odds ratio of 2.37 (OR 1.55-3.62) for DGF and 2.28 (1.62-3.20) for HLA-DR mismatch, respectively, as independent risk factors for early acute rejection but not for late acute rejection. DGF was not implicated in late acute rejection.
Recipient variables
Some modifications in immunosuppression and some alternative pharmacologic intervention in the acceptor have an effect on DGF. A Cochrane meta-analysis of calcium channel blockers for the prevention of acute tubular necrosis in de novo kidney transplants included nine high-quality trials. Perioperative calcium channel blocker therapy was associated with a significant decrease in the incidence of posttransplant acute tubular necrosis (RR 0.57; 95% CI 0.40-0.82) and DGF (RR 0.44; 95% CI 0.28-0.69), although graft loss, mortality, and need for dialysis were not different [46] . Higher serum calcium levels correlated in one study with an increased incidence of DGF, and preoperative calcium blocker therapy had protective properties [47] . A trial with recombinant insulin-like growth factor did not have the expected effect as was seen in an animal model, where it did accelerate recovery from acute renal failure. Neither clearance at day 7, nor at week 6, nor the need for dialysis differed between the treated and the untreated patients. Angiotensin converting enzyme inhibition (ACEi) and angiotensin II receptor blocker (ARB) therapy was started during the peritransplant period. ACEi or ARB therapy did not influence immediate posttransplant renal function or the occurrence of DGF. However, serum creatinine levels decreased significantly faster in patients with ACEi or ARB than in those without therapy. In patients with DGF, ACEi or ARB therapy produced a significantly faster graft recovery.
The variables delaying graft function included the number of previous transplantations, longer cold ischemia times, and male sex [48••] .
Sirolimus-based immunosuppression does not have a more beneficial effect on DGF incidence, compared with antibody induction combined with delayed calcineurin inhibitor initiation at the moment of renal function recovery. Sirolimus significantly prolonged the duration of DGF but had no adverse effect on patient and graft survival at 1 year. Graft function at 1 year was identical in all groups [43, 49] . Stallone et al. [50] treated their de novo renal allograft recipients with basiliximab, steroids, mycophenolate mofetil, and full-dose cyclosporine versus basiliximab, steroids, sirolimus, and low-dose cyclosporine. DGF incidence was similar in both groups, but DGF was significantly prolonged in the sirolimustreated group. At discharge, the creatinine clearance was worse with sirolimus and improved afterwards; at 1 year, no difference in graft function between the two treatment groups was found [50] . Smith et al. [51] observed a significant difference in DGF incidence in their transplanted population: 25% for sirolimus versus 9% for the patients not treated with sirolimus. The sirolimus dose correlated with the DGF incidence, and histology of sirolimus plus tacrolimus-treated allograft revealed intratubular cast formation, composed of degenerating tubular epithelial cells. Further indication for an impairment of tubular regeneration or toxicity was found in an animal study. After 39 hours of cold storage, only 30% kidney graft survival was noted in sirolimus-treated rats (sirolimus trough level 12.0-16.6 ng/mL) versus 100% survival in vehicle-treated animals. After 24 hours of cold storage, survival was identical, but with worse graft function in the sirolimus-treated animals, which showed more tubular necrosis [52] .
In a randomized trial comparing tacrolimus and mycophenolate mofetil or azathioprine and steroids versus cyclosporine, mycophenolate mofetil, and steroids, antibody induction was used only in the patients experiencing DGF. At the 3-year follow-up visit, tacrolimus and mycophenolate mofetil had a significant graft survival and graft functional benefit, compared with their cyclosporine-treated counterparts. The combination of tacrolimus and mycophenolate mofetil with antibody induction was superior as far as DGF was concerned [53] . Two doses of the IL-2 receptor antibody daclizumab were tested in combination with low-dose cyclosporine, mycophenolate mofetil, and steroids. An elevation of the acute rejection rate (23%) and of DGF (51%; DGF defined as absence of reduction in creatinine at day 1) was observed. However, graft function was good and comparable with that in a historic control group treated with standard cyclosporine doses, in which acute rejection and DGF were 31% and 22%, respectively [54] . Induction with daclizumab significantly reduces DGF in patients treated with several combinations of immunosuppressants. Daclizumab, low-dose tacrolimus, mycophenolate mofetil, and steroids diminished the incidence of DGF toward 44% in renal transplants from NHBD [55] . A retrospective analysis of single-center data in older recipients (aged > 60 years) indicated that induction therapy with the IL-2 receptor antibody basiliximab gave a statistically significant lower incidence of DGF compared with the group receiving equine antithymocyte antibodies (ATGAM). Also, acute rejection was significantly lower in the basiliximab group [56] . The effect of intraoperative versus postoperative administration of the polyclonal antithymocyte antibody thymoglobulin was retrospectively analyzed. Intraoperative thymoglobulin was associated with significantly less DGF and a lower mean serum creatinine on postoperative day 10 [57•]. The hypothesis for this difference in timing of administration is that intraoperative administration diminishes ischemia/reperfusion injury by acting on the T cells involved in this process.
Age, blood pressure, Duffy blood type, gene polymorphism, and obesity were also shown to have an effect on the incidence of DGF. Arterial hypertension was independently associated in a retrospective survey of more than 1600 transplant recipients, together with male sex, recipient age, donor age, diabetes, body mass index, the presence of native kidneys, and previous acute rejection [58] . Early diastolic hypertension was inversely associated with the risk of DGF in transplanted kidneys that lacked renal autoregulation; for each unit increase in diastolic blood pressure, the risk of DGF decreased [59] . Obese recipients with a body mass index greater than 30 kg/m 2 experienced significantly more DGF than nonobese recipients (30% vs 5%) [60] . Duffy (a-b-) blood group was associated with DGF, whereas patients with Duffy antigen have a Duffy antigen chemokines receptor, which plays an antiinflammatory role. These latter patients are less vulnerable to DGF [61] . Gene polymorphism of TGF-␤1 was investigated in African Americans. Seventy-seven percent of recipients who experienced acute rejection carried the transforming growth factor-␤1 cytokine expression T/C G/G, high-producer genotype, compared with 52% who experienced DGF. The interferon-␥ T/A intermediate-producer genotype and the IL-10 ATA/ATA low-producer genotype were associated with acute rejection, meaning that identification of recipients with a higher risk for acute rejection or DGF could influence therapeutic intervention [62] .
The markers for DGF in the allograft recipient are IL-18, IL-6, IL-8, and urinary actin and can predict ischemic injury. Lower IL-18 levels were associated with a better immediate allograft function, whereas higher IL-18 levels were associated with DGF. High levels of IL-6, IL-8, and urinary actin in the immediate postoperative phase indicated sustained DGF [63, 64] .
Delayed graft function contributed at least in part to an increased risk for death in the first postoperative year and for late allograft failure. Patients with early acute rejection, DGF, and a lower glomerular filtration rate after transplantation were at increased risk for death within the first year after transplantation. Recipients with comorbid diseases such as diabetes, peripheral vascular disease, and angina pectoris and patients with a long duration of end-stage renal disease had a similar elevated risk for mortality at the end of year 1 [65•]. Ponticelli et al. [66] studied the case records of 864 recipients with a functioning graft at 1 year. The graft half-life was 20.1 years. Plasma creatinine and lowdensity lipoproteins at 1 year, older recipient age, and DGF were associated with late allograft failure.
Miscellaneous factors: hydration protocols of donor and recipient and pretransplant dialysis modality
Earlier studies have clearly demonstrated the effect of maximal hydration of the recipient under peroperative monitoring of the pulmonary arterial pressure (PAP) on the incidence of DGF after kidney transplantation. The frequency of DGF was 36% in a group of patients with a mean PAP less than or equal to 20 mm Hg and a diastolic PAP (DPAP) less than or equal to 15 mm Hg, versus only 6% in recipients whose PAP levels before and at the time of clamp release were greater than 20 mm Hg and a DPAP of greater than 15 mm Hg. [67, 68] .
In this regard, studies from our unit have shown that the pretransplant dialysis modality used in the recipient also had an important impact on the incidence of DGF. In a case-control study, the incidence of DGF, defined as the necessity to perform dialysis after transplantation, was analyzed according to previous treatment with continuous ambulatory peritoneal dialysis (n = 117) or hemodialysis (n = 117) [69] . DGF occurred in 27 patients using continuous ambulatory peritoneal dialysis (23.1%) and 59 patients using hemodialysis (50.4%). A further Cox regression analysis showed that the relative risk for DGF increased with 4% per hour of cold ischemia time and that fluid load decreased the relative risk with 5% per liter [70] . However, peritoneal dialysis as a pretransplantation modality independently modified the relative risk favorably by a factor of 1.6.
The preventive administration of mannitol just before clamp release during renal transplantation surgery reduced the incidence of posttransplant acute tubular necrosis [71] . Similarly, kidneys perfused with a solution containing mannitol had better functional performance and a lower incidence of primary acute renal failure (ARF) than kidneys perfused without mannitol [72] . In two controlled trials, natriuretic peptides were not capable of preventing ARF or improving early renal function [73, 74] .
In a prospective study in brain-dead donors, the use of 6% hydroxy-ethyl-starch 200/0.62 caused impaired graft function [75] . Patients treated with hydroxy-ethylstarch had larger serum creatinine concentrations and required hemodialysis more often than did those in gelatin-treated group. By contrast, a retrospective study for similar types of patients did not demonstrate any adverse effects on kidney function when hydroxy-ethylstarch 450/0.7 or 200/0.5 was compared with gelatin/ albumin [76] .
Conclusion
Published data indicate that not only DGF, defined as requirement for dialysis in the first week, but also nondialyzed SGF has a negative impact on graft survival and on the incidence of acute rejection.
Because of the growing waiting lists, many transplant centers have started to accept not only living-related donors but also ECD, older donors, and NHBD. Whereas the results for living donation were already known to be favorable, the long-term results of well-selected NHBD are surprisingly good.
The process of ischemia/reperfusion injury is already initiated in the brain-dead donor and continues during preservation of the graft. Graft infiltrating T cells, heat shock proteins, and heme oxygenase-1 are concepts that have recently emerged in the literature. Some modifications in immunosuppressive therapy and pharmacologic modulations have different effects on the incidence of DGF. Recipient status variables also play a role in DGF and final graft outcome. DGF contributes to the incidence of acute rejection, impaired graft function, and patient and graft survival. 
